But Berkshire, England-based Celltech is thinly traded and little talked about in the U.S. Lately, it has mostly made it into the press because of a bidding war with Cambridge Antibody Technology (nasdaq: CATG - news - people ) for proteomics pioneer Oxford Glycosciences.